Osier FHA
17 results
Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.Nkumama IN, Ogwang R, Odera D, Musasia F, Mwai K, Nyamako L, Murungi L, Tuju J, Fürle K, Rosenkranz M, Kimathi R, Njuguna P, Hamaluba M, Kapulu MC, Frank R, Osier FHA
Immunity, (2024). 57:1215-1224
Bi-isotype immunoglobulins enhance antibody-mediated neutrophil activity against Plasmodium falciparum parasites.Ogwang R, Murugu L, Nkumama IN, Nyamako L, Kai O, Mwai K, Murungi L, Idro R, Bejon P, Tuju J, Kinyanjui SM, Osier FHA
Front Immunol, (2024). 15:1360220
Antibody-Dependent Respiratory Burst against Plasmodium falciparum Merozoites in Individuals Living in an Area with Declining Malaria Transmission.Mutemi DD, Tuju J, Ogwang R, Nyamako L, Wambui KM, Cruz IR, Villner P, Yman V, Kinyanjui SM, Rooth I, Ngasala B, Färnert A, Osier FHA
Vaccines (Basel), (2024). 12:
Characterization of a novel Plasmodium falciparum merozoite surface antigen and potential vaccine target.Niaré K, Chege T, Rosenkranz M, Mwai K, Saßmannshausen Z, Odera D, Nyamako L, Tuju J, Alfred T, Waitumbi JN, Ogutu B, Sirima SB, Awandare G, Kouriba B, Rayner JC, Osier FHA
Front Immunol, (2023). 14:1156806
Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.Odera DO, Tuju J, Mwai K, Nkumama IN, Fürle K, Chege T, Kimathi R, Diehl S, Musasia FK, Rosenkranz M, Njuguna P, Hamaluba M, Kapulu MC, Frank R, Osier FHA, Abdi AI, Chi PC, de Laurent Z, Jao I, Kamuya D, Kamuyu G, Makale J, Murungi L, Musyoki J, Muthui M, Mwacharo J, Kariuki S, Mwanga D, Mwongeli J, Ndungu F, Njue M, Nyangweso G, Kimani D, Ngoi JM, Musembi J, Ngoto O, Otieno E, Ooko M, Shangala J, Wambua J, Mohammed KS, Omuoyo D, Mosobo M, Kibinge N, Kinyanjui S, Bejon P, Lowe B, Marsh K, Marsh V, Abebe Y, Billingsley PF, Sim BKL, Hoffman SL, James ER, Richie TL, Audi A, Olewe F, Oloo J, Ongecha J, Ongas MO, Koskei N, Bull PC, Hodgson SH, Kivisi C, Imwong M, Murphy SC, Ogutu B, Tarning J, Winterberg M, Williams TN
Sci Transl Med, (2023). 15:eabn5993
Phagocytosis of Plasmodium falciparum ring-stage parasites predicts protection against malaria.Musasia FK, Nkumama IN, Frank R, Kipkemboi V, Schneider M, Mwai K, Odera DO, Rosenkranz M, Furle K, Kimani D, Tuju J, Njuguna P, Hamaluba M, Kapulu MC, Wardemann H, CHMI-SIKA Study Team, Osier FHA
Nat Commun, (2022). 13:4098
Distinct kinetics of antibodies to 111 Plasmodium falciparum proteins identifies markers of recent malaria exposure.Yman V, Tuju J, White MT, Kamuyu G, Mwai K, Kibinge N, Asghar M, Sundling C, Sonden K, Murungi L, Kiboi D, Kimathi R, Chege T, Chepsat E, Kiyuka P, Nyamako L, Osier FHA, Farnert A
Nat Commun, (2022). 13:331
Malaria vaccine roller coaster.Nkumama IN, Osier FHA
Nat Microbiol, (2021). 6:1345-1346
Smashing Stereotypes: Mutual Respect, Key to Embracing Diversity.Osier FHA, Murungi LM
Trends Parasitol, (2021). 37:265-267
Turning Discoveries into Treatments: Immunology in Africa.Osier FHA, Mwandumba HC, Gray CM
Trends Immunol, (2020). 41:1051-1053
Plasmodium falciparum Merozoite Associated Armadillo Protein (PfMAAP) Is Apically Localized in Free Merozoites and Antibodies Are Associated With Reduced Risk of Malaria.Aniweh Y, Nyarko PB, Charles-Chess E, Ansah F, Osier FHA, Quansah E, Thiam LG, Kamuyu G, Marsh K, Conway DJ, Tetteh KKA, Awandare GA
Front Immunol, (2020). 11:505
Serological Profiling for Malaria Surveillance Using a Standard ELISA Protocol.Murungi LM, Kimathi RK, Tuju J, Kamuyu G, Osier FHA
Methods Mol Biol, (2019). 2013:83-90
Antibody responses to merozoite antigens after natural Plasmodium falciparum infection: kinetics and longevity in absence of re-exposure.Yman V, White MT, Asghar M, Sundling C, Sonden K, Draper SJ, Osier FHA, Farnert A
BMC Med, (2019). 17:22
KILchip v1.0: A Novel Plasmodium falciparum Merozoite Protein Microarray to Facilitate Malaria Vaccine Candidate Prioritization.Kamuyu G, Tuju J, Kimathi R, Mwai K, Mburu J, Kibinge N, Chong Kwan M, Hawkings S, Yaa R, Chepsat E, Njunge JM, Chege T, Guleid F, Rosenkranz M, Kariuki CK, Frank R, Kinyanjui SM, Murungi LM, Bejon P, Farnert A, Tetteh KKA, Beeson JG, Conway DJ, Marsh K, Rayner JC, Osier FHA
Front Immunol, (2018). 9:2866
Vaccine candidate discovery for the next generation of malaria vaccines.Tuju J, Kamuyu G, Murungi LM, Osier FHA
Immunology, (2017). 152:195-206
Changes in Malaria Epidemiology in Africa and New Challenges for Elimination.Nkumama IN, O'Meara WP, Osier FHA
Trends Parasitol, (2017). 33:128-140
Targets and Mechanisms Associated with Protection from Severe Plasmodium falciparum Malaria in Kenyan Children.Murungi LM, Sonden K, Llewellyn D, Rono J, Guleid F, Williams AR, Ogada E, Thairu A, Farnert A, Marsh K, Draper SJ, Osier FHA
Infect Immun, (2016). 84:950-963